Monday, 19 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

ULTIMOVACS Stock Is 21% Up In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of ULTIMOVACS (Oslo Børs All-share Index_GI: ULTI.OL) rose by a staggering 21.16% in 10 sessions from $110.6 to $134.00 at 13:44 EST on Tuesday, after three consecutive sessions in a row of gains. Oslo Børs All-share Index_GI is rising 0.84% to $1,377.27, after successive sessions in a row of losses.

About ULTIMOVACS

Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, ULTIMOVACS has a trailing twelve months EPS of $-3.98.

Volatility

ULTIMOVACS's last week, last month's, and last quarter's current intraday variation average was 2.18%, 0.84%, and 2.72%.

ULTIMOVACS's highest amplitude of average volatility was 2.18% (last week), 2.05% (last month), and 2.72% (last quarter).

More news about ULTIMOVACS (ULTI.OL).

Categories

stockMarket

Tags

Stock PriceMarket Session NowStock Market NowPrice UpULTIMOVACSMarket SessionStock Price UpULTI.OLStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Sovereign, Local and Open AI: Infrastructure and Applied Intelligence Scale Up While Frontier-Lab Safety Scrutiny Grows
AI is shifting from cloud-rented models toward locally run, owned and open intelligence. ASUS/NVIDIA RTX Spark laptops pair with Nous Research's Hermes and ComfyUI, and Microsoft pushes hybrid local/cloud Windows. Cisco, NVIDIA and Marvell build open high-bandwidth AI infrastructure, and Hesai supplies real-world data for physical AI. In finance and commerce, Intuit, Zeta, Parloa/TELUS Digital and Snipp embed agentic AI into trusted financial and customer workflows, while OpenAI's math breakthroughs, its security disclosures and an executive's departure from its safety role keep safety and governance scrutiny high.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,397 source documents archived
Query this data → isubstrate.com